Lytix Biopharma AS (OSL:LYTIX)

Norway flag Norway · Delayed Price · Currency is NOK
9.40
+0.02 (0.21%)
Mar 4, 2026, 4:25 PM CET
90.67%
Market Cap 721.32M
Revenue (ttm) n/a
Net Income (ttm) -59.98M
Shares Out 76.90M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,235
Average Volume 58,235
Open 9.64
Previous Close 9.38
Day's Range 9.30 - 9.64
52-Week Range 4.55 - 11.90
Beta -0.46
RSI 52.52
Earnings Date Feb 12, 2026

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 7
Stock Exchange Oslo Børs
Ticker Symbol LYTIX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.